Trials / Completed
CompletedNCT03642600
The Gut Microbiome in Women With Polycystic Ovary Syndrome
Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Testing two different strategies for weight loss intervention and revealing possible changes in composition of gut microbiota, in order to provide more insight in the effect of dietary changes and weight loss treatments on gut microbiome in overweight and obese women with polycystic ovary syndrome (PCOS). The two strategies are: * dietary advice plus myo-inositol and folic acid * dietary advice plus liraglutide, glucagon-like peptide-1 (GLP-1) receptor agonist Primary outcome will be weight loss. Secondary outcomes are longitudinal changes in clinical features associated with PCOS and metabolic syndrome, longitudinal changes in gut microbiome with interventions. Subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | dietary advice plus myo-inositol and folic acid | dietary advice and lifestyle interventions and myo-inositol |
| DRUG | dietary advice plus Liraglutide Pen Injector | dietary advice and lifestyle interventions and liraglutide pen injector |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2020-02-01
- Completion
- 2020-07-03
- First posted
- 2018-08-22
- Last updated
- 2020-11-04
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03642600. Inclusion in this directory is not an endorsement.